Product Details
| Product Name:
Tofimilast |
CAS No.:
185954-27-2 |
| Purity:
99.55% |
Supply Ability:
10g |
| Release date:
2026/08/03 |
Product Introduction
Bioactivity
| Name | Tofimilast |
| Description | Tofimilast (CP-325366), a PDE4 inhibitor, is used potentially for the treatment of asthma and chronic obstructive pulmonary disease. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (132.56 mM), Sonication is recommended.
|
| Keywords | Tofimilast | PDE4 |
| Inhibitors Related | Balipodect | Theophylline monohydrate | D(+)-Raffinose pentahydrate | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Sildenafil citrate | Doxofylline |
| Related Compound Libraries | Bioactive Compounds Library Max | ReFRAME Related Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Clinical Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States